TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 19330379

Group type: EXPERIMENTAL
Intervention: Early oral feeding (EOF)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Traditional oral feeding (TOF)
Number of subjects: 40
Study: 17893385

Group type: EXPERIMENTAL
Intervention: Self‐administered questionnaire
Number of subjects: 523

Group type: EXPERIMENTAL
Intervention: Medical staff interview
Number of subjects: 523

Group type: EXPERIMENTAL
Intervention: Physician interview
Number of subjects: 523

Group type: EXPERIMENTAL
Intervention: WAST‐Short
Number of subjects: 523

Group type: EXPERIMENTAL
Intervention: Overall prevalence of domestic violence
Number of subjects: 523

Group type: EXPERIMENTAL
Intervention: Patient comfort with screening
Number of subjects: 523

Group type: EXPERIMENTAL
Intervention: Clinician comfort with screening
Number of subjects: 523

Group type: EXPERIMENTAL
Intervention: Average time spent screening
Number of subjects: 523
Study: 14699550

Group type: EXPERIMENTAL
Intervention: Drain used
Number of subjects: 53

Group type: COMPARATOR
Intervention: No drain used
Number of subjects: 53
Study: 11865127

Group type: EXPERIMENTAL
Intervention: Diagnostic criteria of reflex sympathetic dystrophy (RSD)
Number of subjects: 73

Group type: COMPARATOR
Intervention: Complex regional pain syndrome (CRPS) diagnostic criteria
Number of subjects: 73
Study: 9215820

Group type: EXPERIMENTAL
Intervention: Droloxifene (DRO) as first-line hormone therapy (HT)
Number of subjects: 94
Study: 8459456

Group type: EXPERIMENTAL
Intervention: Piperacillin (4.5 g, every 6 hours)
Number of subjects: 246

Group type: COMPARATOR
Intervention: Gentamicin (80 mg, every 8 hours) and Metronidazole (500 mg every 6 hours)
Number of subjects: 246
Study: 2943309

Group type: EXPERIMENTAL
Intervention: Paroxetine 15 mg
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Paroxetine 30 mg
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Paroxetine 30 mg (morning administration)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo (bedtime)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo (morning)
Number of subjects: 12
Study: 30035123

Group type: EXPERIMENTAL
Intervention: New material diapers (Group A, n = 41)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Standard diapers (Group B, n = 39)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: New material diapers (Group A)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Standard diapers (Group B)
Number of subjects: 80
Study: 26711859

Group type: EXPERIMENTAL
Intervention: Stendo Pulsating Suit
Number of subjects: 24

Group type: COMPARATOR
Intervention: Intermittent Pneumatic Compression (IPC)
Number of subjects: 24
Study: 25287106

Group type: EXPERIMENTAL
Intervention: PTP-guided ventilation strategy
Number of subjects: 200

Group type: COMPARATOR
Intervention: High-PEEP control
Number of subjects: 200
Study: 22841529

Group type: EXPERIMENTAL
Intervention: Water supplementation
Number of subjects: 168

Group type: COMPARATOR
Intervention: Control group (no water supplementation)
Number of subjects: 168
Study: 20814324

Group type: EXPERIMENTAL
Intervention: Nicotine (8 mg) gum
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo gum
Number of subjects: 24
Study: 18048636

Group type: EXPERIMENTAL
Intervention: Brief protocol including booster sessions
Number of subjects: 6322

Group type: COMPARATOR
Intervention: American Cancer Society's standard protocol with boosters
Number of subjects: 6322
Study: 16383035

Group type: EXPERIMENTAL
Intervention: Subcutaneous injection of recombinant human growth hormone (rhGH)
Number of subjects: 207

Group type: COMPARATOR
Intervention: Subcutaneous injection of isotonic saline (placebo control)
Number of subjects: 207
Study: 11896746

Group type: EXPERIMENTAL
Intervention: Active medication (Potassium bromide 1X, Sodium bromide 2X, Nickel sulfate 3X, Sodium chloride 6X)
Number of subjects: 41

Group type: COMPARATOR
Intervention: Placebo (vehicle)
Number of subjects: 41
Study: 10554537

Group type: EXPERIMENTAL
Intervention: Selenium and vitamin E as antioxidants in addition to standard therapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Reference group with no additional therapy
Number of subjects: 0
Study: 7481869

Group type: EXPERIMENTAL
Intervention: Carboplatin
Number of subjects: 2000

Group type: COMPARATOR
Intervention: Cisplatin
Number of subjects: 2000

Group type: EXPERIMENTAL
Intervention: Carboplatin and cyclophosphamide
Number of subjects: 2000

Group type: COMPARATOR
Intervention: Intraperitoneal cisplatin/IV paclitaxel
Number of subjects: 2000

Group type: COMPARATOR
Intervention: IV paclitaxel/cisplatin regimen
Number of subjects: 2000

Group type: EXPERIMENTAL
Intervention: Dose-intensive regimen incorporating two courses of carboplatin
Number of subjects: 2000

Group type: EXPERIMENTAL
Intervention: High-dose carboplatin/cyclophosphamide/mitoxantrone
Number of subjects: 2000

Group type: EXPERIMENTAL
Intervention: High-dose cisplatin/cyclophosphamide/thiotepa
Number of subjects: 2000
Study: 2038933

Group type: EXPERIMENTAL
Intervention: High-dose epinephrine (5 mg)
Number of subjects: 68

Group type: COMPARATOR
Intervention: Standard-dose epinephrine (1 mg)
Number of subjects: 68
Study: 7462674

Group type: EXPERIMENTAL
Intervention: 0.05% clobetasol propionate cream
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 0.1% beta‐methasone 17‐valerate cream
Number of subjects: 0

Group type: COMPARATOR
Intervention: cream base
Number of subjects: 0

Group type: COMPARATOR
Intervention: clobetasone butyrate 0.05% cream
Number of subjects: 0

Group type: COMPARATOR
Intervention: hydrocortisone 1% cream
Number of subjects: 0
Study: 30583108

Group type: EXPERIMENTAL
Intervention: ACD (anterior cervical discectomy)
Number of subjects: 109

Group type: EXPERIMENTAL
Intervention: ACDF (anterior cervical discectomy and fusion)
Number of subjects: 109

Group type: EXPERIMENTAL
Intervention: ACDA (anterior cervical disc arthroplasty)
Number of subjects: 109

Group type: EXPERIMENTAL
Intervention: Quality of life (EQ-5D)
Number of subjects: 109

Group type: EXPERIMENTAL
Intervention: Adjacent segment degeneration parameters
Number of subjects: 109
Study: 27752866

Group type: EXPERIMENTAL
Intervention: Tailored Physical Activity Internet Intervention
Number of subjects: 205

Group type: COMPARATOR
Intervention: Wellness Contact Control Internet Group
Number of subjects: 205
Study: 26105555

Group type: EXPERIMENTAL
Intervention: Web-based intervention (four modules: information exchange website, bulletin board system, individualized online counseling, animation game)
Number of subjects: 202

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 202
Study: 23820460

Group type: EXPERIMENTAL
Intervention: Tolvaptan administered via nasogastric tube (crushed tablet in suspension)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Tolvaptan tablets swallowed intact (oral administration)
Number of subjects: 28
Study: 23204686

Group type: EXPERIMENTAL
Intervention: Mifepristone 200 mg followed by intravaginal misoprostol 600 μg and 400 μg every 3 hours up to 5 doses
Number of subjects: 200

Group type: COMPARATOR
Intervention: Misoprostol alone (600 μg followed by 400 μg every 3 hours up to 5 doses)
Number of subjects: 200
Study: 19299774

Group type: EXPERIMENTAL
Intervention: Hematocrit of 25% during surgery
Number of subjects: 104

Group type: COMPARATOR
Intervention: Hematocrit of 35% during surgery
Number of subjects: 104

Group type: EXPERIMENTAL
Intervention: D-TGA subjects during CPB cooling
Number of subjects: 104

Group type: EXPERIMENTAL
Intervention: D-TGA subjects with > or =5 min of deep hypothermic circulatory arrest (DHCA)
Number of subjects: 104
Study: 17162029

Group type: EXPERIMENTAL
Intervention: Aerobic exercise
Number of subjects: 231

Group type: COMPARATOR
Intervention: Placebo/stretching and motion exercises
Number of subjects: 231
Study: 15465981

Group type: EXPERIMENTAL
Intervention: Ziprasidone
Number of subjects: 269

Group type: COMPARATOR
Intervention: Olanzapine
Number of subjects: 269
Study: 11479249

Group type: EXPERIMENTAL
Intervention: Stenting (n=600; diabetic, 112)
Number of subjects: 1205

Group type: EXPERIMENTAL
Intervention: CABG (n=605; diabetic, 96)
Number of subjects: 1205

Group type: COMPARATOR
Intervention: Stenting (n=600; nondiabetic)
Number of subjects: 1205

Group type: COMPARATOR
Intervention: CABG (n=605; nondiabetic)
Number of subjects: 1205
Study: 9928923

Group type: EXPERIMENTAL
Intervention: Clozapine + Paroxetine (20 mg)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Clozapine (2.5 mg/kg)
Number of subjects: 14
Study: 8306217

Group type: EXPERIMENTAL
Intervention: Desmopressin acetate (DDAVP)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 44
Study: 2556978

Group type: EXPERIMENTAL
Intervention: IgG treatment (500 mg/kg, 12 weekly infusions)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Control (no treatment)
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: IgG treatment
Number of subjects: 28

Group type: COMPARATOR
Intervention: Control
Number of subjects: 28
Study: 5811679

Group type: EXPERIMENTAL
Intervention: Corn-oil diet
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard diet
Number of subjects: 0
Study: 31182492

Group type: EXPERIMENTAL
Intervention: Healthy Eating (HE)
Number of subjects: 436

Group type: COMPARATOR
Intervention: No Healthy Eating (No HE)
Number of subjects: 436

Group type: EXPERIMENTAL
Intervention: Physical Activity (PA)
Number of subjects: 436

Group type: COMPARATOR
Intervention: No Physical Activity (No PA)
Number of subjects: 436
Study: 28558781

Group type: EXPERIMENTAL
Intervention: Multi-component intervention including sit-stand workstation, individual health coaching, and organisational support strategies
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Sit-stand workstations
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Social support from team leaders and other participants
Number of subjects: 28
Study: 26007710

Group type: EXPERIMENTAL
Intervention: Pimobendan
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study: 22763027

Group type: EXPERIMENTAL
Intervention: Preoperative chemoradiation therapy (CRT)
Number of subjects: 222
Study: 21167347

Group type: EXPERIMENTAL
Intervention: Smoking cessation
Number of subjects: 1504

Group type: COMPARATOR
Intervention: Continuing smoking
Number of subjects: 1504
Study: 18164990

Group type: EXPERIMENTAL
Intervention: FF 55 microg
Number of subjects: 558

Group type: EXPERIMENTAL
Intervention: FF 110 microg
Number of subjects: 558

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 558
Study: 17186736

Group type: EXPERIMENTAL
Intervention: Qingling Dingxuan Decoction (QDD)
Number of subjects: 39

Group type: COMPARATOR
Intervention: Flunarizine
Number of subjects: 39
Study: 12540791

Group type: EXPERIMENTAL
Intervention: Doppler echocardiography
Number of subjects: 165

Group type: EXPERIMENTAL
Intervention: Right heart catheterization
Number of subjects: 165

Group type: EXPERIMENTAL
Intervention: Initial phase of transplantation
Number of subjects: 165

Group type: EXPERIMENTAL
Intervention: Waiting for a graft
Number of subjects: 165
Study: 10692616

Group type: EXPERIMENTAL
Intervention: Chronic NSAID use (>/=2 months)
Number of subjects: 19364

Group type: COMPARATOR
Intervention: Control group (not exposed to NSAIDs)
Number of subjects: 19364
Study: 8982891

Group type: EXPERIMENTAL
Intervention: Sevoflurane-nitrous oxide
Number of subjects: 50

Group type: COMPARATOR
Intervention: Propofol-nitrous oxide
Number of subjects: 50
Study: 1595998

Group type: EXPERIMENTAL
Intervention: Aminophylline (6 mg/kg loading dose over 20 min, followed by 0.9 mg/kg/h maintenance infusion)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Oxygen (100% O2 breathing)
Number of subjects: 9
Study: 6372707

Group type: EXPERIMENTAL
Intervention: 25 mg artificial surfactant in 1 ml saline
Number of subjects: 12

Group type: COMPARATOR
Intervention: Saline only
Number of subjects: 12
Study: 29727330

Group type: EXPERIMENTAL
Intervention: Side‐by‐side unregistered image guidance (IG)
Number of subjects: 36

Group type: COMPARATOR
Intervention: No guidance control (NG)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Perfect augmented reality (AR)
Number of subjects: 36
Study: 30138795

Group type: EXPERIMENTAL
Intervention: COP (copulation)
Number of subjects: 24

Group type: COMPARATOR
Intervention: CON (control)
Number of subjects: 24
Study: 27273433

Group type: EXPERIMENTAL
Intervention: Pimecrolimus
Number of subjects: 1091

Group type: COMPARATOR
Intervention: Vehicle
Number of subjects: 1091
Study: 25127011

Group type: COMPARATOR
Intervention: Alendronate discontinuation (placebo)
Number of subjects: 404
Study: 22325683

Group type: EXPERIMENTAL
Intervention: Two-hour arm crank ergometer exercise at 60% maximum oxygen consumption
Number of subjects: 16
Study: 20103076

Group type: EXPERIMENTAL
Intervention: FLS proficiency‐based curriculum training (n = 9)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Control group (n = 8)
Number of subjects: 19
Study: 18358540

Group type: EXPERIMENTAL
Intervention: Lamotrigine (LTG) 200 mg/day over 8 weeks
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Lithium (Li) at least 900 mg/day over 2 weeks (serum level 0.6-1.2 mEq/L)
Number of subjects: 72

Group type: COMPARATOR
Intervention: Lithium (Li)
Number of subjects: 72
Study: 15972272

Group type: EXPERIMENTAL
Intervention: Isocaloric diet
Number of subjects: 10

Group type: COMPARATOR
Intervention: 4-day complete fast
Number of subjects: 10
Study: 11835029

Group type: EXPERIMENTAL
Intervention: ST recovery <30% in the single lead with maximum ST elevation
Number of subjects: 766

Group type: EXPERIMENTAL
Intervention: ST recovery 30% to 70% in the single lead with maximum ST elevation
Number of subjects: 766

Group type: EXPERIMENTAL
Intervention: ST recovery >70% in the single lead with maximum ST elevation
Number of subjects: 766

Group type: EXPERIMENTAL
Intervention: ST recovery >70% in patients with TIMI grade 3 flow
Number of subjects: 766

Group type: EXPERIMENTAL
Intervention: ST recovery measured as the sum of voltage changes of either ST deviation or ST elevation
Number of subjects: 766

Group type: EXPERIMENTAL
Intervention: Age, ST recovery (continuous variable), diabetes, female gender
Number of subjects: 766

Group type: EXPERIMENTAL
Intervention: Ejection fraction and TIMI flow grade at 3 weeks
Number of subjects: 766
Study: 10079449

Group type: EXPERIMENTAL
Intervention: 4.0 mm capsulorhexis
Number of subjects: 58

Group type: COMPARATOR
Intervention: 6.0 mm capsulorhexis
Number of subjects: 58

Group type: COMPARATOR
Intervention: Comparison between 4.0 mm and 6.0 mm capsulorhexis
Number of subjects: 58
Study: 7673534

Group type: EXPERIMENTAL
Intervention: Multisystemic therapy (MST)
Number of subjects: 176

Group type: COMPARATOR
Intervention: Individual therapy (IT)
Number of subjects: 176
Study: 1710009

Group type: EXPERIMENTAL
Intervention: Aprotinin (Trasylol) high dosage (about 800 mg) during extracorporeal circulation
Number of subjects: 22

Group type: COMPARATOR
Intervention: Control group (no aprotinin)
Number of subjects: 22
Study: 7224261

Group type: EXPERIMENTAL
Intervention: Cephalexin (250 mg orally q.i.d. x 5 days)
Number of subjects: 394

Group type: COMPARATOR
Intervention: No antibiotic (control group)
Number of subjects: 394
Study: 31477783

Group type: EXPERIMENTAL
Intervention: General sleep and activity guidelines
Number of subjects: 547

Group type: EXPERIMENTAL
Intervention: Activity intensity (60 min of energetic play) and sleep regularity (consistent sleep and wake times)
Number of subjects: 547

Group type: EXPERIMENTAL
Intervention: Meeting all three guidelines at a given age
Number of subjects: 547

Group type: EXPERIMENTAL
Intervention: Adherence to all three guidelines at earlier ages
Number of subjects: 547
Study: 28931929

Group type: EXPERIMENTAL
Intervention: 9602 A. cristatum expressed sequence tag-sequence-tagged site (EST-STS) markers for PCR amplification and experimental screening; 6063 polymorphic EST-STS markers specific for the A. cristatum P genome in the single-receipt wheat background.
Number of subjects: 0
Study: 25501100

Group type: EXPERIMENTAL
Intervention: OPCAB with BMC treatment
Number of subjects: 90

Group type: COMPARATOR
Intervention: OPCAB with saline (control)
Number of subjects: 90
Study: 23510529

Group type: EXPERIMENTAL
Intervention: Fluoxetine (10-20 mg/day) plus vitamin C (1000 mg/day)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Fluoxetine (10-20 mg/day) plus placebo
Number of subjects: 12
Study: 21608221

Group type: EXPERIMENTAL
Intervention: Huazhuo Jiedu Recipe (HJR)
Number of subjects: 229

Group type: COMPARATOR
Intervention: Weifuchun Tablet (Control)
Number of subjects: 229
Study: 19849835

Group type: EXPERIMENTAL
Intervention: Embedded motor imagery training
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Added motor imagery training
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard physiotherapy intervention (Control Group)
Number of subjects: 0
Study: 16573982

Group type: EXPERIMENTAL
Intervention: Team-skills training (Cohort 2 and Cohort 3)
Number of subjects: 295

Group type: EXPERIMENTAL
Intervention: Team-skills training (Cohort 3)
Number of subjects: 295

Group type: COMPARATOR
Intervention: No preparation (Cohort 1)
Number of subjects: 295
Study: 15017515

Group type: EXPERIMENTAL
Intervention: 5-aminosalicylic acid 1.0 g 3 times a day
Number of subjects: 321

Group type: EXPERIMENTAL
Intervention: 5-aminosalicylic acid 0.5 g 3 times a day
Number of subjects: 321

Group type: EXPERIMENTAL
Intervention: 5-aminosalicylic acid 1.5 g 3 times a day
Number of subjects: 321

Group type: EXPERIMENTAL
Intervention: 5-aminosalicylic acid (all doses)
Number of subjects: 321
Study: 10673129

Group type: EXPERIMENTAL
Intervention: Water Drinking Test (WDT)
Number of subjects: 36
Study: 9066215

Group type: EXPERIMENTAL
Intervention: Amalgam adhesive as the principal mode of retention
Number of subjects: 0

Group type: COMPARATOR
Intervention: Traditional pin-retained amalgams
Number of subjects: 0
Study: 8346133

Group type: EXPERIMENTAL
Intervention: 201-thallium/99m-technetium subtraction scanning (Tl/Tc)
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: 10 MHz ultrasound
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Both techniques (Tl/Tc and ultrasound)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Tl/Tc scanning
Number of subjects: 25

Group type: COMPARATOR
Intervention: Ultrasound
Number of subjects: 25

Group type: COMPARATOR
Intervention: Both techniques together
Number of subjects: 25
Study: 3554818

Group type: EXPERIMENTAL
Intervention: Methylphenidate (5 to 20 mg/d)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 30274655

Group type: EXPERIMENTAL
Intervention: Metformin plus healthy lifestyle instruction
Number of subjects: 61

Group type: COMPARATOR
Intervention: Healthy lifestyle instruction alone
Number of subjects: 61
Study: 26108445

Group type: EXPERIMENTAL
Intervention: Topical combination therapy with maxacalcitol ointment and betamethasone butyrate propionate ointment (BBP)
Number of subjects: 27

Group type: COMPARATOR
Intervention: Topical corticosteroid (BBP) alone
Number of subjects: 27
Study: 25187436

Group type: EXPERIMENTAL
Intervention: Sodium- and fluid-restricted diet (0.8 g/day sodium and 800 mL/day fluid)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Unrestricted diet (4 g/day sodium and unlimited fluid intake)
Number of subjects: 0
Study: 24097171

Group type: EXPERIMENTAL
Intervention: Cold water immersion at 15 °C (C15)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Contrast water therapy (CT)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Thermoneutral water immersion at 34 °C (T34)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Cycling at 40% peak (AR)
Number of subjects: 9
Study: 20534765

Group type: EXPERIMENTAL
Intervention: Testosterone enanthate 25 mg
Number of subjects: 103

Group type: EXPERIMENTAL
Intervention: Testosterone enanthate 50 mg
Number of subjects: 103

Group type: EXPERIMENTAL
Intervention: Testosterone enanthate 125 mg
Number of subjects: 103

Group type: EXPERIMENTAL
Intervention: Testosterone enanthate 300 mg
Number of subjects: 103

Group type: EXPERIMENTAL
Intervention: Testosterone enanthate 600 mg
Number of subjects: 103

Group type: EXPERIMENTAL
Intervention: Testosterone administration
Number of subjects: 103
Study: 18404076

Group type: EXPERIMENTAL
Intervention: Continuous beta-blocker (BB)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Standard of care (Control)
Number of subjects: 42
Study: 16511414

Group type: EXPERIMENTAL
Intervention: Nevirapine
Number of subjects: 259
Study: 15217715

Group type: EXPERIMENTAL
Intervention: Low-dose aspirin (in a double-blind, placebo-controlled, randomized clinical trial)
Number of subjects: 1630

Group type: COMPARATOR
Intervention: Control group (placebo)
Number of subjects: 1630

Group type: EXPERIMENTAL
Intervention: Antiplatelet therapy
Number of subjects: 1630
Study: 11517126

Group type: EXPERIMENTAL
Intervention: Propofol/remifentanil
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Sevoflurane/remifentanil
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Propofol/remifentanil and Sevoflurane/remifentanil
Number of subjects: 0
Study: 9768937

Group type: EXPERIMENTAL
Intervention: Modified ultrafiltration (MUF)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Control (conventional ultrafiltration)
Number of subjects: 100
Study: 7810251

Group type: EXPERIMENTAL
Intervention: Dexamethasone (500 mg intravenous infusion within 3 h after trauma, followed by 200 mg after 3 h, then 8 times 200 mg at 6 hourly intervals, total dose 2.3 g in 51 hours)
Number of subjects: 300

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 300
Study: 3292634

Group type: EXPERIMENTAL
Intervention: Ragweed challenge
Number of subjects: 18

Group type: COMPARATOR
Intervention: Unchallenged blisters from allergic and nonallergic patients
Number of subjects: 18

Group type: COMPARATOR
Intervention: Ragweed challenge in nonallergic patients
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Correlation of PGD2 levels
Number of subjects: 18
Study: 29856103

Group type: EXPERIMENTAL
Intervention: Atropine
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Clonidine
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60

Group type: COMPARATOR
Intervention: Saline
Number of subjects: 60
Study: 28742911

Group type: EXPERIMENTAL
Intervention: TTM for 48 hours (n=176)
Number of subjects: 355

Group type: COMPARATOR
Intervention: TTM for 24 hours (n=179)
Number of subjects: 355

Group type: EXPERIMENTAL
Intervention: TTM for 48 hours
Number of subjects: 355

Group type: COMPARATOR
Intervention: TTM for 24 hours
Number of subjects: 355
Study: 26285766

Group type: EXPERIMENTAL
Intervention: Iniparib with monthly temozolomide (mTMZ) dosing (150‐200 mg/m(2) days 1‐5/28 days)
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Iniparib with continuous temozolomide (cTMZ) dosing (75 mg/m(2)/days × 6 weeks)
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Iniparib
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Recommended phase 2 dosing of iniparib
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Efficacy study of TMZ/RT + iniparib followed by TMZ + iniparib
Number of subjects: 43